| Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 14604739 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Even within the normal range, aldosterone levels are linked to end-organ toxicity and mortality in patients with hypertension. Treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers does not sufficiently reduce plasma aldosterone levels. OBJECTIVE: This study was conducted to assess the long-term safety profile and efficacy of the selective aldosterone blocker eplerenone. METHODS: This was a multicenter, open-label, uncontrolled trial in patients with mild to moderate essential hypertension. After a 1-week washout of previous antihypertensive medications, eplerenone was initiated at 50 mg once daily; the dose was titrated to a maximum of 200 mg/d to achieve a diastolic blood pressure <90 mm Hg and a systolic blood pressure <140 mm Hg. Thereafter, another antihypertensive agent could be added and titrated once, or another agent could be substituted for eplerenone. Eplerenone treatment was continued for up to 14 months in a subset of patients. RESULTS: Five hundred eighty-six patients were enrolled in the study. Their adjusted mean blood pressure (BP) at baseline was 150/96 mm Hg. The majority (80.4%) were white; 51.5% were male and 48.5% were female; 62.3% were between the ages of 45 and 64 years and 21.7% were aged >64 years. Three hundred eighty-five patients (65.7%) completed the study; 98 (16.7%) were withdrawn due to treatment failure (only 4.8% of them after month 4), and 40 (6.8%) were withdrawn due to treatment-emergent adverse events. Four hundred thirty-three of 582 (74.4%) patients in the intent-to-treat population achieved BP control during eplerenone treatment: 261 (44.8%) received eplerenone monotherapy and 172 (30.0%) received eplerenone plus another antihypertensive agent. CONCLUSIONS: Eplerenone therapy was effective in the treatment of mild to moderate hypertension over a 14-month period, either as monotherapy or in combination with another antihypertensive agent. Use of eplerenone was well tolerated in the population studied. |
| | |
Authors:
|
Ellen D Burgess; Yves Lacourcière; Luis M Ruilope-Urioste; Suzanne Oparil; Jay H Kleiman; Scott Krause; Barbara Roniker; Clement Maurath |
Related Documents
:
|
2527199 - Low dose atrial natriuretic factor in primary aldosteronism: renal, hemodynamic, and va... 965299 - Plasma renin activity, angiotensin ii, and aldosterone during intense heat stress. 7016779 - The renin-angiotensin system and aldosterone in hypertension: a brief review of some as... 6752169 - Circadian blood pressure and renin, aldosterone, cortisol, and prolactin levels in hype... 21463699 - The dynamic face of respiratory research: understanding the effect of airway disease on... 645899 - Aldosterone metabolism in isolated perfused rat kidney. 18071779 - High sensitivity c-reactive protein and endothelial function in chilean patients with h... 12794419 - Arterial oxygenation and oxygen delivery after hemoglobin-based oxygen carrier infusion... 9119849 - Soft-tissue balancing with pressure distribution during total knee arthroplasty. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical therapeutics Volume: 25 ISSN: 0149-2918 ISO Abbreviation: Clin Ther Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-11-07 Completed Date: 2003-12-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7706726 Medline TA: Clin Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 2388-404 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Calgary, Calgary, Alberta, Canada. ellen.burgess@calgaryhealthregion.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aldosterone Antagonists / adverse effects, therapeutic use* Antihypertensive Agents / therapeutic use* Dose-Response Relationship, Drug Drug Therapy, Combination Female Humans Hypertension / drug therapy* Male Middle Aged Spironolactone / adverse effects, analogs & derivatives*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Antihypertensive Agents; 0/eplerenone; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.
Next Document: An open-label, prospective, observational study of the incidence of coronary artery disease in patie...